2019 ASCCP Risk-Based Management Consensus Guidelines: Updates Through 2023

J Low Genit Tract Dis. 2024 Jan 1;28(1):3-6. doi: 10.1097/LGT.0000000000000788.


This Research Letter summarizes all updates to the 2019 Guidelines through September 2023, including: endorsement of the 2021 Opportunistic Infections guidelines for HIV+ or immunosuppressed patients; clarification of use of human papillomavirus testing alone for patients undergoing observation for cervical intraepithelial neoplasia 2; revision of unsatisfactory cytology management; clarification that 2012 guidelines should be followed for patients aged 25 years and older screened with cytology only; management of patients for whom colposcopy was recommended but not completed; clarification that after treatment for cervical intraepithelial neoplasia 2+, 3 negative human papillomavirus tests or cotests at 6, 18, and 30 months are recommended before the patient can return to a 3-year testing interval; and clarification of postcolposcopy management of minimally abnormal results.

MeSH terms

  • Colposcopy
  • Consensus
  • Female
  • Humans
  • Papillomaviridae
  • Papillomavirus Infections* / complications
  • Papillomavirus Infections* / diagnosis
  • Pregnancy
  • Risk Management
  • Uterine Cervical Dysplasia*
  • Uterine Cervical Neoplasms* / diagnosis
  • Uterine Cervical Neoplasms* / therapy
  • Vaginal Smears